

## Combined Estrogen–Progestogen Menopausal Therapy

### References to Supplementary Web Tables, Section 2

- Bakken K, Alsaker E, Eggen AE, Lund E (2004). Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. *Int J Cancer*, 112:130–134.[doi:10.1002/ijc.20389](https://doi.org/10.1002/ijc.20389) PMID:15305384
- Beral V, Banks E, Reeves G, Bull D; Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*, 362:1330–1331.[doi:10.1016/S0140-6736\(03\)14596-5](https://doi.org/10.1016/S0140-6736(03)14596-5) PMID:12927427
- Beral V, Bull D, Green J, Reeves G; Million Women Study Collaborators (2007). Ovarian cancer and hormone replacement therapy in the Million Women Study. *Lancet*, 369:1703–1710.[doi:10.1016/S0140-6736\(07\)60534-0](https://doi.org/10.1016/S0140-6736(07)60534-0) PMID:17512855
- Campagnoli C, Clavel-Chapelon F, Kaaks R *et al.* (2005). Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. *J Steroid Biochem Mol Biol*, 96:95–108.[doi:10.1016/j.jsbmb.2005.02.014](https://doi.org/10.1016/j.jsbmb.2005.02.014) PMID:15908197
- Corrao G, Zambon A, Conti V *et al.* (2008). Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. *Ann Oncol*, 19:150–155.[doi:10.1093/annonc/mdm404](https://doi.org/10.1093/annonc/mdm404) PMID:17785762
- Danforth KN, Tworoger SS, Hecht JL *et al.* (2007). A prospective study of postmenopausal hormone use and ovarian cancer risk. *Br J Cancer*, 96:151–156.[doi:10.1038/sj.bjc.6603527](https://doi.org/10.1038/sj.bjc.6603527) PMID:17179984
- Dinger JC, Heinemann LA, Möhner S *et al.* (2007). Colon cancer risk and different HRT formulations: a case-control study. *BMC Cancer*, 7:76.[doi:10.1186/1471-2407-7-76](https://doi.org/10.1186/1471-2407-7-76) PMID:17488513
- Fournier A, Berrino F, Riboli E *et al.* (2005). Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer*, 114:448–454.[doi:10.1002/ijc.20710](https://doi.org/10.1002/ijc.20710) PMID:15551359
- Lacey JV Jr, Brinton LA, Leitzmann MF *et al.* (2006). Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. *J Natl Cancer Inst*, 98:1397–1405.[doi:10.1093/jnci/djj375](https://doi.org/10.1093/jnci/djj375) PMID:17018786
- Lacey JV Jr, Brinton LA, Lubin JH *et al.* (2005). Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. *Cancer Epidemiol Biomarkers Prev*, 14:1724–1731.[doi:10.1158/1055-9965.EPI-05-0111](https://doi.org/10.1158/1055-9965.EPI-05-0111) PMID:16030108
- Lacey JV Jr, Leitzmann MF, Chang SC *et al.* (2007). Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. *Cancer*, 109:1303–1311.[doi:10.1002/cncr.22525](https://doi.org/10.1002/cncr.22525) PMID:17315161
- Lee S, Kolonel L, Wilkens L *et al.* (2006). Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. *Int J Cancer*, 118:1285–1291.[doi:10.1002/ijc.21481](https://doi.org/10.1002/ijc.21481) PMID:16170777
- Li CI, Daling JR, Malone KE *et al.* (2006). Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev*, 15:946–954.[doi:10.1158/1055-9965.EPI-05-0881](https://doi.org/10.1158/1055-9965.EPI-05-0881) PMID:16702375
- Li CI, Malone KE, Porter PL *et al.* (2003). Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. *JAMA*, 289:3254–3263.[doi:10.1001/jama.289.24.3254](https://doi.org/10.1001/jama.289.24.3254) PMID:12824206
- Magnusson C, Baron JA, Correia N *et al.* (1999). Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. *Int J Cancer*, 81:339–344.[doi:10.1002/\(SICI\)1097-0215\(19990505\)81:3<339::AID-IJC5>3.0.CO;2-6](https://doi.org/10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6) PMID:10209946
- Moorman PG, Schildkraut JM, Calingaert B *et al.* (2005). Menopausal hormones and risk of ovarian cancer. *Am J Obstet Gynecol*, 193:76–82.[doi:10.1016/j.ajog.2004.11.013](https://doi.org/10.1016/j.ajog.2004.11.013) PMID:16021062
- Nazeri K, Khatibi A, Nyberg P *et al.* (2006). Colorectal cancer in middle-aged women in relation to hormonal status: a report from the Women’s Health in the Lund Area (WHILA) study. *Gynecol Endocrinol*, 22:416–422.[doi:10.1080/09513590600900378](https://doi.org/10.1080/09513590600900378) PMID:17012102

- Newcomb PA, Titus-Ernstoff L, Egan KM *et al.* (2002). Postmenopausal estrogen and progestin use in relation to breast cancer risk. *Cancer Epidemiol Biomarkers Prev*, 11:593–600. [PMID:12101105](#)
- Newcomb PA, Zheng Y, Chia VM *et al.* (2007). Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. *Cancer Res*, 67:7534–7539. [doi:10.1158/0008-5472.CAN-06-4275](#) [PMID:17671225](#)
- Olsson HL, Ingvar C, Bladström A (2003). Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. *Cancer*, 97:1387–1392. [doi:10.1002/cncr.11205](#) [PMID:12627501](#)
- Porch JV, Lee IM, Cook NR *et al.* (2002). Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). *Cancer Causes Control*, 13:847–854. [doi:10.1023/A:1020617415381](#) [PMID:12462550](#)
- Rosenberg LU, Einarisdóttir K, Friman EI *et al.* (2006b). Risk factors for hormone receptor-defined breast cancer in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*, 15:2482–2488. [doi:10.1158/1055-9965.EPI-06-0489](#) [PMID:17164374](#)
- Rosenberg LU, Palmer JR, Wise LA, Adams-Campbell LL (2006a). A prospective study of female hormone use and breast cancer among black women. *Arch Intern Med*, 166:760–765. [doi:10.1001/archinte.166.7.760](#) [PMID:16606813](#)
- Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000). Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. *J Natl Cancer Inst*, 92:328–332. [doi:10.1093/jnci/92.4.328](#) [PMID:10675382](#)
- Rossing MA, Cushing-Haugen KL, Wicklund KG *et al.* (2007). Menopausal hormone therapy and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*, 16:2548–2556. [doi:10.1158/1055-9965.EPI-07-0550](#) [PMID:18086757](#)
- Stahlberg C, Pedersen AT, Andersen ZJ *et al.* (2004b). Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. *Br J Cancer*, 91:644–650. [PMID:15238982](#)
- Stahlberg C, Pedersen AT, Lynge E *et al.* (2004a). Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. *Int J Cancer*, 109:721–727. [doi:10.1002/ijc.20016](#) [PMID:14999781](#)
- Strom BL, Schinnar R, Weber AL *et al.* (2006). Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. *Am J Epidemiol*, 164:775–786. [doi:10.1093/aje/kwj316](#) [PMID:16997897](#)
- Weiss JM, Saltzman BS, Doherty JA *et al.* (2006). Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. *Am J Epidemiol*, 164:56–62. [doi:10.1093/aje/kwj152](#) [PMID:16675538](#)
- Weiss LK, Burkman RT, Cushing-Haugen KL *et al.* (2002). Hormone replacement therapy regimens and breast cancer risk(1). *Obstet Gynecol*, 100:1148–1158. [doi:10.1016/S0029-7844\(02\)02502-4](#) [PMID:12468157](#)
- Wu AH, Yu MC, Tseng CC, Pike MC (2007). Body size, hormone therapy and risk of breast cancer in Asian-American women. *Int J Cancer*, 120:844–852. [doi:10.1002/ijc.22387](#) [PMID:17131315](#)